UK Common Frameworks Page summary: UK government publications relating to the UK Common Frameworks programme. Change made: Update to the DfT section Time updated: 4:00pm, 27 February 2026
Ben KempMarch 5, 2026
Doing business with the health sector: a guide for buyers and small and medium-sized enterprises (SMEs) Page summary: A clear, practical guide to help buyers and SMEs build a fair, inclusive environment that can deliver better health outcomes and support SME growth. Change made: First published. Time updated: 12:00pm, 24 February 2026 National Cancer Plan for England Page summary: Details…
Ben KempMarch 5, 2026
Machinery safety legislation: call for evidence Page summary: We are inviting views on the introduction across the UK of measures in the EU Machinery Regulation 2023/1230. Change made: Call for evidence response published. Time updated: 10:01am, 25 February 2026
Ben KempMarch 5, 2026
How will regulators enable safe AI-powered innovation: joint letter from DSIT Secretary of State and DBT Secretary of State Page summary: Joint letter from DSIT Secretary of State Liz Kendall, DBT Secretary of State Peter Kyle, and the relevant departmental Secretaries of State requesting regulators to publish a plan on how they intend to enable safe AI-powered innovation. Change made:…
Ben KempMarch 5, 2026
Singapore: UK Science and Innovation Network summary Page summary: A summary from UK Science and Innovation Network (SIN) on science and innovation in Singapore including UK SIN priorities and successes. Change made: Guidance document uploaded to reflect this year’s updates. Time updated: 4:22am, 23 February 2026 Software Security Ambassadors Scheme Page summary: A scheme to champion secure software development and…
Ben KempMarch 5, 2026
Dear Members, IMDRF have issued Industry guidance on the considerations for the selection of IMDRF Adverse Event Terminology N86: Final 2026 It includes examples of which 8, 12 and 18 are specific to IVDs. Considerations for the selection of IMDRF Adverse Event Terminology – A Guide for Industry Partners and Healthcare Providers View article...
Ben KempMarch 5, 2026
New Publication! Strengthen Tumor Market Testing with CLSI C65 Biochemical tumor marker plays a critical role in diagnosis, monitoring, and clinical decision making. With increasing pressure on laboratories to ensure accuracy and consistency across preexamination, examination, and postexamination processes, the new CLSI C65 standard provides the guidance needed to reduce risk and improve confidence in patient results. Practical…
Ben KempMarch 2, 2026